The Life Sciences Report: As I look at your coverage list, the first thing that pops into my mind is that you are following a lot of sophisticated technology, biotechnology, specialty pharma, enabling technologies and more. Do you have a theme, or are you just looking for growth wherever you can find it?
Alex Daley: Our coverage is ultimately about underaddressed or completely unaddressed markets. A lot of great technology is out there—far more than any one person or team of people can cover across the entire biotech spectrum, let alone when you add in specialty pharma, … [visit site to read more]
Similar posts:- Smart money vs. ‘dumb’ money investing 85% of U.S. individual investors were unable to pass...
- Pick Biotech Winners Like a Pro: John McCamant The Life Sciences Report: John, in February we discussed secular...
- Analyst Bets on Extraordinary Science and Clinical Data: Greg Wade The Life Sciences Report: The Wedbush Management Conference was held...
